[Pulmonary involvement in rare systemic diseases-part 1 : Pulmonary manifestations in the context of hematological, immunological, histiocytic, and hepatological diseases and chronic inflammatory bowel disease].
{"title":"[Pulmonary involvement in rare systemic diseases-part 1 : Pulmonary manifestations in the context of hematological, immunological, histiocytic, and hepatological diseases and chronic inflammatory bowel disease].","authors":"Jasmin Happe, Thomas Frauenfelder","doi":"10.1007/s00117-025-01497-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pulmonary manifestations occur in a wide range of multisystemic diseases and can affect the lung parenchyma, airways, vascular system, and respiratory musculature in various ways. In particular, severe and potentially life-threatening pulmonary complications are of major concern in systemic conditions such as immunological and hematological disorders. The increasing incidence of hematological, gastrointestinal, and hepatological diseases in recent years-driven in part by lifestyle factors in Western industrialized nations-highlights the growing clinical relevance of these entities and the need for a comprehensive understanding of their pulmonary manifestations. Additional diagnostic and therapeutic challenges arise from drug-induced lung injury and late complications of therapy, such as those following stem cell transplantation.</p><p><strong>Results: </strong>High-resolution computed tomography (HRCT) plays a pivotal role in this context. It allows for the early detection of characteristic pulmonary abnormalities and thus forms the basis for timely therapeutic intervention.</p><p><strong>Conclusion: </strong>Targeted HRCT imaging is therefore crucial to improving clinical outcomes and preserving the quality of life in affected patients.</p>","PeriodicalId":74635,"journal":{"name":"Radiologie (Heidelberg, Germany)","volume":" ","pages":"766-776"},"PeriodicalIF":0.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457517/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiologie (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00117-025-01497-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pulmonary manifestations occur in a wide range of multisystemic diseases and can affect the lung parenchyma, airways, vascular system, and respiratory musculature in various ways. In particular, severe and potentially life-threatening pulmonary complications are of major concern in systemic conditions such as immunological and hematological disorders. The increasing incidence of hematological, gastrointestinal, and hepatological diseases in recent years-driven in part by lifestyle factors in Western industrialized nations-highlights the growing clinical relevance of these entities and the need for a comprehensive understanding of their pulmonary manifestations. Additional diagnostic and therapeutic challenges arise from drug-induced lung injury and late complications of therapy, such as those following stem cell transplantation.
Results: High-resolution computed tomography (HRCT) plays a pivotal role in this context. It allows for the early detection of characteristic pulmonary abnormalities and thus forms the basis for timely therapeutic intervention.
Conclusion: Targeted HRCT imaging is therefore crucial to improving clinical outcomes and preserving the quality of life in affected patients.